Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
China's national blood disease hospital in Tianjin, where the CD19 binder behind the CAR-T inati-cel was made and many of the country's leukaemia and CAR-T trials run.
Overview
The national centre for haematology within CAMS, with the State Key Laboratory of Experimental Hematology; origin of the CNCT19 CAR-T (inaticabtagene autoleucel, approved 2023 for adult B-ALL with Juventas), large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.
- State Key Laboratory of Experimental Hematology
- CAR-T development
- Leukaemia registries and trials
Pages like this
not linked directly; found by shared links- InstitutionPeking University People's Hospital
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia, CAR-T cell therapy and the tag china.
- PersonXiaojun Huang
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag china.
- InstitutionNational Cancer Center of China
Shares Cancer Hospital, Chinese Academy of Medical Sciences and the tag china.
- TrialDAWNA-1
Shares Cancer Hospital, Chinese Academy of Medical Sciences and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- TrialRELIANCE
Shares CAR-T cell therapy and the tag china.
- PersonSaijuan Chen
Shares Acute myeloid leukaemia and the tag china.
- CompanyIASO Biotherapeutics
Shares CAR-T cell therapy and the tag china.